Nobel winner won't give up on elusive HIV vaccine
A Nobel Prize-winning biologist says that researchers are no closer to developing a vaccine against HIV than they were 20 years ago, when the scientific quest began. The key challenge to the virus,
Can a vaccine control high blood pressure?
The Chicago Sun-Times profiles Cytos' work on a new blood pressure vaccine. Just like new development work being done on vaccines for cancer, asthma and psoriasis, the trick is to identify a protein
Flu jab missing the mark in seasonal campaign
There's growing evidence around the U.S. that the flu jab offers only marginal protection against the seasonal ailment. In Texas, doctors say this year's flu vaccine guarded against less than 30
SPOTLIGHT: Advaxis vaccine demonstrates potential
Advaxis says it is developing a vaccine that could be effective in combating cervical cancer. The company says that its vaccine has proven safe in women with advanced cervical cancer in a small
ALSO NOTED: Canada sees low takeup for free cervical cancer shots; NYU advances brain cancer vaccine; and much more...
Iomai vax patch guards against traveler's diarrhea
Iomai is touting the results of a mid-stage study of its vaccine patch for traveler's diarrhea. Iomai researchers say that the patch delivered a robust immune response among the 160 volunteers in the
Booming vaccine biz swells Sanofi's revenue
A sign of the times? When Sanofi-Aventis presented its 2007 results earlier this week, it trumpeted the 14.5 percent sales growth in its vaccines group. That's more than double its pharma growth--and
Sanofi licenses technology for new TB vaccine
Sanofi Pasteur has struck a licensing deal with the Statens Serum Institut of Denmark covering the use of its technology for a new tuberculosis vaccine. The pact includes SSI's Intercell IC31
Vaccines miss their mark in seasonal flu campaign
Each year vaccine makers create a cocktail of antigens designed to stand guard against the various versions of the flu making the rounds in winter. But this year the CDC concludes that most of the
SPOTLIGHT: Sanofi files new vaccine tech
Sanofi Pasteur has submitted the first vaccine delivered by an intradermal microinjection system for European approval. The vaccine is delivered to the dermal layer, triggering a response in
ALSO NOTED: Acambis inks smallpox contract; Yellow fever outbreak; Researchers see promise for stomach flu vaccines; and much m
Researchers five years from prostate cancer vax
Australia's Mater Medical Research Institute is in Phase I clinical trials with a prostate cancer vaccine that it believes could be approved in five years. The researchers are using technology to
France to probe GSK, Sanofi vaccination campaign
French authorities are investigating GlaxoSmithKline and Sanofi Pasteur over an anti-hepatitis B vaccination campaign in the 1990s. At issue is whether the companies fully disclosed the shot's
Cold feet at FDA over Cervarix approval?
Chimp virus plays key role in malaria vaccine
A new blend of a genetically modified chimp adenovirus and a malaria gene is proving promising as a potential vaccine against malaria. The adenovirus is used to spur an immune response against
SPOTLIGHT: Distrust can overcome data
Despite fresh evidence that the MMR vaccine jab does not raise the risk of autism, observers say that the deep level of public distrust for the drug industry will keep this kernel of misinformation
ALSO NOTED: University provides free HPV shots; Intercell reports successful mid-stage hep C study; Tattooing effective in deli
Researchers develop needle-free vaccine delivery
South Korean researchers have successfully tested a new approach to delivering vaccines, applying it under the tongue rather than through a needle. In a mouse study, the under-the-tongue approach
Study: Thoughts can impact vaccine efficacy
A patient's thoughts and feelings play a big role in determining just how effective their annual flu shot can be, says a new study from the University of Wisconsin. In the study, researchers divided
Scientists tackle vaccine for nicotine addiction
An in-development vaccine that weans addicts from their substance of choice has shown the most promise against cocaine addiction so far, but its developers are testing it against other substances

